Abstract
In addition to a variety of other techniques used in T-cell epitope identification, mass spectrometery coupled to liquid chromatography have now become an important and sensitive tool in separation, detection, and sequence analysis of highly complex natural major histocompatibility complex (MHC) ligand mixtures. In this article, we present current strategies for the identification of MHC eluted peptides using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) with a particular recall to those presented in the context of the non classical human leukocytes antigen (HLA) class I molecule HLA-E. In addition we also discuss the advantages and disadvantages of the methods available in the literature to concentrate and fractionate the peptides prior to analysis by mass spectrometry. An application of our method for isolation and characterization of peptides presented in the context of HLA-E is finally reported.
Keywords: High-performance liquid chromatography, HLA-E, mass- spectrometry, peptides
Current Pharmaceutical Design
Title: HPLC and MS Analysis for the Identification and Characterisation of Peptides Presented in the Context of the Non-Classical Human Leukocytes Antigen (HLA) Class I Molecule HLA-E
Volume: 15 Issue: 28
Author(s): Enrico Millo and Gianluca Damonte
Affiliation:
Keywords: High-performance liquid chromatography, HLA-E, mass- spectrometry, peptides
Abstract: In addition to a variety of other techniques used in T-cell epitope identification, mass spectrometery coupled to liquid chromatography have now become an important and sensitive tool in separation, detection, and sequence analysis of highly complex natural major histocompatibility complex (MHC) ligand mixtures. In this article, we present current strategies for the identification of MHC eluted peptides using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) with a particular recall to those presented in the context of the non classical human leukocytes antigen (HLA) class I molecule HLA-E. In addition we also discuss the advantages and disadvantages of the methods available in the literature to concentrate and fractionate the peptides prior to analysis by mass spectrometry. An application of our method for isolation and characterization of peptides presented in the context of HLA-E is finally reported.
Export Options
About this article
Cite this article as:
Millo Enrico and Damonte Gianluca, HPLC and MS Analysis for the Identification and Characterisation of Peptides Presented in the Context of the Non-Classical Human Leukocytes Antigen (HLA) Class I Molecule HLA-E, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105126
DOI https://dx.doi.org/10.2174/138161209789105126 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Small-molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK and Mdm-2 Interaction, and Blocks Breast and Colon Tumorigenesis in vivo
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in Cancer
Anti-Cancer Agents in Medicinal Chemistry KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension
Current Cancer Drug Targets Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II A)
Current Medicinal Chemistry Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Neuropeptide Y and Cancer Anorexia
Current Medicinal Chemistry - Central Nervous System Agents